No Data
Huabei Pharmaceutical: Report for the first quarter of 2025
First Quarter Report of 2025.
North China Pharmaceutical (600812.SH): The finance company plans to convert 1 billion yuan of undistributed profits into registered capital in proportion to each Shareholder's original shareholding ratio.
On April 23, Gelonghui reported that North China Pharmaceutical (600812.SH) announced that in order to enhance the financial company's capital strength, improve its ability to withstand risks, optimize its regulatory Indicators, expand its Business scale, increase Shareholder equity value, and provide more investment returns for Shareholders, the financial company intends to increase the registered capital by 1 billion yuan from undistributed profits in proportion to each Shareholder's original shareholdings. The company will contribute 0.2 billion yuan from its undistributed profits, Jizhong Energy Resources Group will contribute 0.45 billion yuan from its undistributed profits, and Jizhong Energy will contribute 0.35 billion yuan from its undistributed profits. After the capital increase is completed, each Shareholder's shareholding will be.
North China Pharmaceutical (600812.SH): The holding subsidiary plans to reduce capital in a targeted manner.
On April 23, Glonghui reported that North China Pharmaceutical (600812.SH) announced that on April 23, 2025, the company would hold the 20th meeting of the 11th Board of Directors, where it reviewed and approved the proposal regarding the directed capital reduction of its controlling subsidiary. The company, Huasheng Company, and Jianxin Investment agreed to sign the "Directed Capital Reduction Agreement," implementing the directed capital reduction of Huasheng Company. After the capital reduction is completed, Jianxin Investment will exit Huasheng Company, with its shareholding ratio reduced from the original 47.7389% to 0%. The reduction compensation is proposed to be 0.3 billion yuan (the specific amount is subject to the final signed agreement); to be paid by Huasheng Company to Jianxin Investment in cash.
North China Pharmaceutical (600812.SH): AI technology has not been applied in pharmaceutical research, production, and other aspects.
Globe Union reported on April 16 that North China Pharmaceutical (600812.SH) stated on the investor interaction platform that the company is currently not applying AI technology in pharmaceutical research, development, and production.
North China Pharmaceutical (600812.SH): The deployment work of the DeepSeek large model has been initiated.
On April 16, Glonghui reported that North China Pharmaceutical (600812.SH) stated on the investor interaction platform that the company has currently begun the deployment work of the DeepSeek large model, mainly applied in its internal knowledge base and business areas such as regulations and rule inquiries.
North China Pharmaceutical Company.Ltd (SHSE:600812) Not Doing Enough For Some Investors As Its Shares Slump 28%
